The Effects of Nicotine on Cortical Excitability After Exercise: A Double-Blind Randomized, Placebo-controlled, Crossover Study.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

The use of smokeless tobacco/nicotine products is common among athletes, but clear evidence for their positive or negative effect on sports performance is lacking.

Nicotine is a psychoactive substance involved in numerous neuronal processes including cortical excitability.

Transcranial magnetic stimulation (TMS) was used to measure changes in corticomotor excitability (motor-evoked potentials, MEPs) and electromyography of leg muscles during maximal voluntary contractions (MVC) to assess changes in muscle contractions.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults and adults, men only.

Before and after aerobic exercise and with or without nicotine treatment, MEPs and MVCs were measured.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Electromyography, Evoked Potentials, Motor, Exercise, Motor Cortex, Muscle Contraction, Nicotine and Nicotinic Agonists.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Journal of clinical psychopharmacology), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.